CRBP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.595

+104.49%

-1.462

+5.18%

-1.488

+3.33%

Estimates Revision

The market is revising No Change the revenue expectations for Corbus Pharmaceuticals Holdings, Inc. (CRBP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.69%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.77%

In Past 3 Month

Stock Price

Go Down

-7.69%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 44.38 USD with a low forecast of 28.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.480

Low

28.00

Averages

44.38

High

53.00

Current: 9.480

Low

28.00

Averages

44.38

High

53.00

RBC Capital

Outperform

maintain

$53

2025-12-11

New

Reason

RBC Capital

Price Target

$53

2025-12-11

New

maintain

Outperform

Reason

RBC Capital notes that Corbus Pharmaceuticals has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call to discuss the data in detail. Early hints at efficacy and possibility Corbus could navigate a therapeutic window better than prior CB1 efforts should draw attention to this under-the-radar asset, with more robust de-risking data potentially only a few quarters away. At a $35M EV, with a cancer drug in '701 RBC views as low-risk, and a higher-risk but potentially very large-opportunity obesity asset, the firm believes the company is undervalued. The firm has an Outperform rating on the shares with a price target of $53.

Stifel

Stephen Willey

Buy

maintain

$28 -> $32

2025-12-04

Reason

Stifel

Stephen Willey

Price Target

$28 -> $32

2025-12-04

maintain

Buy

Reason

Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."

RBC Capital

Brian Abrahams

Outperform

downgrade

$55 -> $53

2025-11-13

Reason

RBC Capital

Brian Abrahams

Price Target

$55 -> $53

2025-11-13

downgrade

Outperform

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Corbus Pharmaceuticals to $53 from $55 but keeps an Outperform rating on the shares. Following ESMO updates, the potential $500M sales opportunity for '701 in HNSCC and $350M sales opportunity in cervical cancer have been better de-risked, the analyst tells investors in a research note. RBC adds that investors are still not fully appreciating Corbus's potential large out-year sales opportunities across oncology and obesity.

Mizuho

NULL -> Outperform

maintain

$32 -> $39

2025-10-29

Reason

Mizuho

Price Target

$32 -> $39

2025-10-29

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Corbus Pharmaceuticals to $39 from $32 and keeps an Outperform rating on the shares.

Piper Sandler

Overweight

maintain

$35 -> $51

2025-10-20

Reason

Piper Sandler

Price Target

$35 -> $51

2025-10-20

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Corbus Pharmaceuticals to $51 from $35 and keeps an Overweight rating on the shares. The firm says that the company's CRB-701 continues to look meaningfully active in heavily pre-treated HNSCC and cervical cancers in its Phase 1/2 ESMO update, with ORR of 48% in HNSCC and 38% in cervical at the 3.6 mg/kg dose - meaningfully higher than the bar set by Merus' petosemtamab in HNSCC and Tivdak in cervical.

Oppenheimer

Outperform -> Outperform

downgrade

$56 -> $53

2025-08-06

Reason

Oppenheimer

Price Target

$56 -> $53

2025-08-06

downgrade

Outperform -> Outperform

Reason

Oppenheimer lowered the firm's price target on Corbus Pharmaceuticals to $53 from $56 and keeps an Outperform rating on the shares. On Tuesday, the company reported Q2 results, highlighting updated clinical data for CRB-701 to be presented at ESMO in October for the Nectin-4 targeting ADC, the firm notes.

Valuation Metrics

The current forward P/E ratio for Corbus Pharmaceuticals Holdings Inc (CRBP.O) is -1.58, compared to its 5-year average forward P/E of -3.25. For a more detailed relative valuation and DCF analysis to assess Corbus Pharmaceuticals Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.25

Current PE

-1.58

Overvalued PE

2.64

Undervalued PE

-9.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.94

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.58

Undervalued EV/EBITDA

-3.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

78.62

Current PS

0.00

Overvalued PS

232.83

Undervalued PS

-75.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2235.89% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 2235.89% over the last month.

Sold

Bought

CRBP News & Events

Events Timeline

No data

News

9.0

12-11SeekingAlpha

Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913

9.0

12-11Newsfilter

Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients

9.0

12-11NASDAQ.COM

Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update

People Also Watch

Frequently Asked Questions

What is Corbus Pharmaceuticals Holdings Inc (CRBP) stock price today?

The current price of CRBP is 9.48 USD — it has decreased -2.27 % in the last trading day.

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s business?

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

What is the price predicton of CRBP Stock?

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s revenue for the last quarter?

Corbus Pharmaceuticals Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s earnings per share (EPS) for the last quarter?

Corbus Pharmaceuticals Holdings Inc. EPS for the last quarter amounts to -1.90 USD, increased 65.22 % YoY.

What changes have occurred in the market's expectations for Corbus Pharmaceuticals Holdings Inc (CRBP)'s fundamentals?

How many employees does Corbus Pharmaceuticals Holdings Inc (CRBP). have?

Corbus Pharmaceuticals Holdings Inc (CRBP) has 28 emplpoyees as of December 16 2025.

What is Corbus Pharmaceuticals Holdings Inc (CRBP) market cap?

Today CRBP has the market capitalization of 166.40M USD.